… sample in the USA never heard about biosimilars [6]. Therefore, … improve the oncology patient’s
knowledge of biosimilars via … patients’ awareness of major topics related to biosimilars as …

… gained from our training to improve patients’ understanding of cancer treatment options. …
Published studies on hematology/oncology team members and their knowledge of biosimilars …

… of expanded access to biologics and biosimilars on patient costs, and greater …
biosimilar was approved and marketed in the US as a supportive treatment for a hematology–oncology …

… We in fact explored such learning styles in our study which focused on knowledge and
awareness of biosimilars among patients attending oncology practices in Colorado[10]. Similar to …

… teams in Colorado, USA toward SDM and biosimilars. We assessed … among gastroenterology
teams in sharing knowledge about SDM and biosimilars with their colleagues and patients, …

… knowledge of biosimilars in the US. Of these, two were conducted prior to oncology biosimilar
… an overview of academic oncology clinicians’ current understanding of biosimilars and the …

… Colorado). Because all questions were not answered by every … a lack of awareness about
biosimilars among providers. … of knowledge, competence, and confidence among oncologists …

… The main therapeutic areas represented were oncology/onco-haematology with 29 … USA
… Several gaps in respondents’ knowledge about biosimilars were noted including safety, …

… co-developed by Kantar with Ellis Consulting, an independent recruiter that has grown and
maintained the panel for over 20 years. This co… the same level of knowledge, awareness, and …

… oncology biosimilars and identifies current knowledge gaps in … A US study of patients with
various types of cancers and … participants had limited awareness of biosimilars. Furthermore, …